Heaton KM - Search Results

1

Effect of thalidomide on gastrointestinal toxic effects of irinotecan.

Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, Hauer-Jensen M. Govindarajan R, et al. Among authors: heaton km. Lancet. 2000 Aug 12;356(9229):566-7. doi: 10.1016/s0140-6736(00)02586-1. Lancet. 2000. PMID: 10950238 Clinical Trial.

2

Central venous catheter placement in patients with disorders of hemostasis.

Mumtaz H, Williams V, Hauer-Jensen M, Rowe M, Henry-Tillman RS, Heaton K, Mancino AT, Muldoon RL, Klimberg VS, Broadwater JR, Westbrook KC, Lang NP. Mumtaz H, et al. Am J Surg. 2000 Dec;180(6):503-5; discussion 506. doi: 10.1016/s0002-9610(00)00552-3. Am J Surg. 2000. PMID: 11182407

3

Prognostic implications of DNA index in patients with stage III cutaneous melanoma.

Heaton KM, Rippon MB, el-Naggar A, Tucker SL, Ross MI, Balch CM. Heaton KM, et al. Am J Surg. 1993 Dec;166(6):648-52; discussion 652-3. doi: 10.1016/s0002-9610(05)80672-5. Am J Surg. 1993. PMID: 8273843

4

Cytokine combinations in immunotherapy for solid tumors: a review.

Heaton KM, Grimm EA. Heaton KM, et al. Cancer Immunol Immunother. 1993 Sep;37(4):213-9. doi: 10.1007/BF01518513. Cancer Immunol Immunother. 1993. PMID: 8348559 Review.

5

Surgical management and prognostic factors in patients with subungual melanoma.

Heaton KM, el-Naggar A, Ensign LG, Ross MI, Balch CM. Heaton KM, et al. Ann Surg. 1994 Feb;219(2):197-204. doi: 10.1097/00000658-199402000-00012. Ann Surg. 1994. PMID: 8129491 Free PMC article.

6

Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma.

Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, Ross MI. Heaton KM, et al. Ann Surg Oncol. 1998 Jun;5(4):322-8. doi: 10.1007/BF02303495. Ann Surg Oncol. 1998. PMID: 9641453

7

Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer.

Heaton KM, Peoples GE, Singletary SE, Feig BW, Ross MI, Ames FC, Buchholz TA, Strom EA, McNeese MD, Hunt KK. Heaton KM, et al. Ann Surg Oncol. 1999 Jan-Feb;6(1):102-8. doi: 10.1007/s10434-999-0102-8. Ann Surg Oncol. 1999. PMID: 10030422

8

Local-regional control in breast cancer patients with a possible genetic predisposition.

Freedman LM, Buchholz TA, Thames HD, Strom EA, McNeese MD, Hortobagyi GN, Singletary SE, Heaton KM, Hunt KK. Freedman LM, et al. Among authors: heaton km. Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):951-7. doi: 10.1016/s0360-3016(00)00761-6. Int J Radiat Oncol Biol Phys. 2000. PMID: 11072150

9

Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2.

Heaton KM, Grimm EA. Heaton KM, et al. Hum Immunol. 1995 Mar;42(3):274-80. doi: 10.1016/0198-8859(94)00106-z. Hum Immunol. 1995. PMID: 7759316

10

Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy.

Heaton KM, Ju G, Grimm EA. Heaton KM, et al. Cancer Res. 1993 Jun 1;53(11):2597-602. Cancer Res. 1993. PMID: 8495422

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page